Sonnet BioTherapeutics Holdings, Inc. (SONN)
- Previous Close
1.7500 - Open
1.7702 - Bid --
- Ask --
- Day's Range
1.7301 - 1.7973 - 52 Week Range
1.0800 - 26.4000 - Volume
9,532 - Avg. Volume
102,274 - Market Cap (intraday)
5.433M - Beta (5Y Monthly) 1.12
- PE Ratio (TTM)
-- - EPS (TTM)
-0.8300 - Earnings Date May 8, 2024 - May 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
23.00
Sonnet BioTherapeutics Holdings, Inc., a biotechnology company, owns a platform for biologic medicines of single or bifunctional action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead product candidate is SON-1010, a fully human single-chain version of interleukin 12 that is in Phase 1b/2a clinical trial for the treatment of solid tumor indications, including ovarian cancer, non-small cell lung cancer, and head and neck cancer. The company is also developing SON-080, a fully human version of interleukin 6, which is in Phase 1b/I2a clinical trail to treat chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy; and SON-1210, a bispecific compound for solid tumor indications, including colorectal cancer. It has a license agreement with New Life Therapeutics Pte, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin-6. The company is headquartered in Princeton, New Jersey.
www.sonnetbio.comRecent News: SONN
Performance Overview: SONN
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SONN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SONN
Valuation Measures
Market Cap
5.43M
Enterprise Value
2.60M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
26.16
Price/Book (mrq)
2.11
Enterprise Value/Revenue
20.11
Enterprise Value/EBITDA
-0.18
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-175.81%
Return on Equity (ttm)
--
Revenue (ttm)
129.18k
Net Income Avi to Common (ttm)
-14.46M
Diluted EPS (ttm)
-0.8300
Balance Sheet and Cash Flow
Total Cash (mrq)
3.02M
Total Debt/Equity (mrq)
7.26%
Levered Free Cash Flow (ttm)
-13.56M